Table 1 Baseline characteristics of patients enrolled in training (Asian patients) and validation (European patients) cohort.
Feature type | Feature – median (IQR) / n (%) | All (n = 3129) | Training cohort (n = 637) | Validation cohort (n = 2492) |
|---|---|---|---|---|
patient-related | Gender – Male | 1951 (62.3) | 270 (42.4) | 1681 (67.5) |
patient-related | Gender – Female | 1178 (37.7) | 367 (57.5) | 811 (32.5) |
patient-related | Age | 68 (61–76) | 68 (61–76) | 68 (61–76) |
tumor-related | Grading – G1/Low Grade | 127 (4) | 112 (17.6) | 15 (0.6) |
tumor-related | Grading – G2 | 394 (12.6) | 5 (0.8) | 389 (15.6) |
tumor-related | Grading – G3/High grade | 2608 (83.3) | 520 (81.6) | 2088 (83.8) |
tumor-related | pT – pT0 | 17 (0.5) | 2 (0.3) | 15 (0.6) |
tumor-related | pT – pTa | 631 (20.2) | 104 (16.4) | 527 (21.2) |
tumor-related | pT – pTis | 55 (1.8) | 7 (1.1) | 48 (1.9) |
tumor-related | pT – pT1 | 713 (22.8) | 158 (24.8) | 555 (22.2) |
tumor-related | pT – PT2 | 612 (19.6) | 139 (21.8) | 473 (19.0) |
tumor-related | pT – pT3 | 945 (30.2) | 191 (30.0) | 754 (30.2) |
tumor-related | pT – pT4 | 156 (4.9) | 36 (5.7) | 120 (4.9) |
tumor-related | pN – pNx | 2179 (69.6) | 504 (79.1) | 1675 (67.2) |
tumor-related | pN – pN0 | 699 (22.3) | 104 (16.3) | 595 (23.8) |
tumor-related | pN – pN1 | 236 (7.5) | 14 (2.2) | 222 (9) |
tumor-related | pN – pN2 | 15 (0.5) | 15 (2.4) | |
tumor-related | multi-focality – Yes | 795 (25.4) | 205 (32.2) | 590 (23.7) |
tumor-related | multi-focality – No | 2334 (74.6) | 432 (67.8) | 1902 (76.3) |
tumor-related | CIS – Yes | 633 (20.2) | 60 (9.4) | 573 (23.3) |
tumor-related | CIS – No | 2496 (79.8) | 577 (90.6) | 1919 (76.7) |
tumor-related | Lymphovascular invasion – Yes | 1078 (34.5) | 500 (78.5) | 578 (23.2) |
tumor-related | Lymphovascular invasion – No | 2051 (65.5) | 137 (21.5) | 1914 (76.8) |
